Bacteria as tumour-targeting vectors

Lancet Oncology

Volumn 4, Issue 9, 2003, Pages 548-556

  Pawelek, John M ^a   Low, K Brooks ^a   Bermudes, David ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Vion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ACICLOVIR; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; CARBON 14; COLICIN; CYTOKINE; CYTOSINE DEAMINASE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOSTATIN; ENDOTOXIN; FIALURIDINE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; LACTULOSE; LIPID A; LUCIFERASE; NITROREDUCTASE; NUCLEOSIDE ANALOG; PRODRUG; SPECTINOMYCIN; TETRACYCLINE; THYMIDINE KINASE; TOXIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM; BIFIDOBACTERIUM; CANCER RADIOTHERAPY; CANCER THERAPY; CLOSTRIDIUM; DRUG ACTIVATION; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TARGETING; DRUG USE; GENE AMPLIFICATION; GENE SEQUENCE; GENE TRANSFER; GENE VECTOR; GENETIC CODE; GENETIC ENGINEERING; HUMAN; IMMUNOMODULATION; INJECTION SITE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA; SEPTIC SHOCK; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; GENETICS; NEOPLASM;

ANTINEOPLASTIC AGENTS; BACTERIA; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 0141653956     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01194-X     Document Type: Review

References (74)

1. Hall S.S. A commotion in the blood 1998 Henry Holt and Company New York
2. Coley W.B. Contribution to the knowledge of sarcoma Ann Surgery 14 1891 199-220
3. Coley W.B. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus Am J Med Sci 131 1906 375-430
4. Fehleisen F. Die etiologie des erysipel 1883 48 Theodor Fischer Berlin
5. Nauts H.C. Swift W.E. Coley B.L. The treatment of malignant tumors by bacterial toxins as developed by the late William B Coley, MD, reviewed in the light of modern research Cancer Res 6 1946 205-216
6. Nauts H.C. Fowler G.A.A. Bogatko F.H. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man Acta Medica Scandinavica 145 suppl 276 1953 1-105
7. Carswell E.A. Old L.J. Kassel R.L. et al. An endotoxin induced serum factor that causes necrosis of tumors Proc Natl Acad Sci USA 72 1975 3666-3670
8. Berg A.A. Baltimore D. An essential role for NF-κB in preventing TNFα-induced death Science 274 1996 782-784
9. Zbar B. Bernstein I. Tanaka T. Rapp H.J. Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovix (strain BCG) Science 17 1970 1217-1218
10. Goonewardene M. Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients Med Oncol Tumor Parmacother 10 1993 145-158
11. Axelrod R.S. Havas H.F. Murasko D.M. et al. Effect of the mixed bacterial vaccine on the immune response of patients with non-small cell lung cancer and refractory malignancies Cancer 61 1988 2219-2230
12. Liu S. Aaronson H. Mitola D.J. et al. Potent antitumor activity of a urokinase-activated engineered anthrax toxin Proc Natl Acad Sci USA 100 2003 657-662
13. Parker R.C. Plummber H.C. Siebenmann C.O. Chapman M.G. Effect of histolyticus infection and toxin on transplantable mouse tumors Proc Soc Exp Biol Med 66 1947 461-465
14. Gericke D. Engelbart K. Oncolysis by clostridia. II experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal Cancer Res 24 1964 217-221
15. Möse J.R. Möse G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma Cancer Res 24 1964 212-216
16. Thiele E.H. Arison R.N. Boxer G.E. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors Cancer Res 24 1964 222-233
17. Thiele E.H. Arison R.N. Boxer G.E. Oncolysis by clostridia. IV. Effect of nonpathogenic clostridia spores in normal and pathological tissues Cancer Res 24 1964 234-238
18. Engelbart K. Gericke D. Oncolysis by clostridia. V. Transplanted tumors of the hamster Cancer Res 24 1964 239-243
19. Carey W.W. Holland J.F. Whang H.Y. et al. Clostridial oncolysis in man Eur J Cancer 3 1967 37-46
20. Fox M.E. Lemmon M.J. Mauchline M.L. et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia Gene Therapy 3 1996 173-178
21. Minton N.P. Mauchline M.L. Lemmon M.J. et al. Chemotherapeutic tumour targeting using clostridial spores FEMS Microbiol Rev 17 1995 357-364
22. Lemmon M.J. van Zijl P. Fox M.E. et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment Gene Therapy 8 1997 791-796
23. Theys J. Landuyt W. Nuyts S. et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum Cancer Gene Ther 8 2001 294-297
24. Nuyts S. Mellaert I.V. Theys J. et al. Clostridium spores for tumor-specific drug delivery Anticancer Drugs 13 2002 115-125s
25. Liu S.-C. Minton N.P. Giaccia A.J. Brown J.M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis Gene Ther 9 2002 291-296
26. Nuyts S. Van Mellaert L. Theys J. et al. Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation Gene Ther 8 2002 1197-1201
27. Dang L.H. Bettegowda C. Huso D.L. et al. Combination bacteriolytic therapy for the treatment of experimental tumors Proc Natl Acad Sci USA 98 2001 15155-15160
28. Sekine K. Ohta J. Onishi M. et al. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis Biol Pharm Bull 18 1995 148-153
29. Rhee Y.K. Bae E.A. Kim S.Y. et al. Antitumor activity of Bifidobacterium spp. isolated from a healthy Korean Arch Pharm Res 23 2000 482-487
30. Kimura N.T. Taniguchi S. Aoki K. Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration Cancer Res 40 1980 2061-2068
31. Yazawa K. Fujimori M. Nakamura T. et al. Bifodobacterium longum as a delivery system for cancer gene therapy of chemically induced rat mammary tumors Breast Cancer Res Treat 66 2001 165-170
32. Yazawa K. Fujimori M. Amano J. et al. Bifodobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors Cancer Gene Ther 7 2000 269-274
33. Li X. Fu G.-F. Fan Y.-R. et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth Cancer Gene Ther 10 2003 105-111
34. Graham F.O. Coleman P.N. Infection of a secondary carcinoma by Salmonella montevideo BMJ 1 1952 1116
35. Giel C.P. Abscess formation in a pheochromocytoma New Engl J Med 251 1954 980-982
36. Gill G.V. Holden A. A malignant pleural effusion infected with Salmonella enteritidis Thorax 51 1996 104-105
37. Johnson P.H. Macfarlane J.T. Commentary: Pleural empyema and malignancy-Another direction Thorax 51 1996 107-108
38. Bacon G.A. Burrows T.W. Yates M. The effects of biochemical mutation on the virulence of bacterium typhosum: the loss of virulence of certain mutants Br J Exp Path 32 1951 85-96
39. Bacon G.A. Burrows T.W. Yates M. The effects of biochemical mutation on the virulence of bacterium typhosum: the virulence of mutants Br J Exp Path 31 1950 714-724
40. Bacon G.A. Burrows T.W. Yates M. The effects of biochemical mutation on the virulence of bacterium typhosum: the induction and isolation of mutants Br J Exp Path 31 1950 703-713
41. Pawelek J. Low K.B. Bermudes D. Tumor-targeted Salmonella as a novel anti-cancer vector Cancer Res 57 1997 4537-4544
42. Luo X. Li Z. Lin S. et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models Oncol Res 12 2001 501-508
43. Low K.B. Ittensohn M. Le T. et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumour-targeting in vivo Nat Biotechnol 17 1999 37-41
44. Bermudes D. Low B. Pawelek J. Tumour-targeted Salmonella: highly selective delivery vectors Habib N. Cancer Gene Therapy 2000 415-432 Plenum Press New York
45. Clairmont C. Lee K.C. Pike J. et al. Biodistribution and genetic stability of the novel antitumour agent VNP20009, a genetically modified strain of Salmonella typhimurium J Infect Dis 181 2000 1996-2002
46. Bermudes D. Low B. Pawelek J. Tumour-targeted Salmonella: strain development and expression of the HSV TK effector gene Walther W. Stein U. Gene therapy: methods and protocols 2000 419-436 Humana Press Totowa
47. Bermudes D. Low K.B. Pawelek J. et al. Tumour-specific Salmonella-based cancer therapy Biotechnology and Genetic Engineering Review 18 2001 219-233
48. Li Z. Lang W. Runyan J. et al. Tissue distribution and in vivo expression of cytosine deaminase by TAPET-CD, a genetically engineered strain of Salmonella typhimurium as an anti-tumour vector Am Assoc Cancer Res 42 2001 687
49. Lin S.L. Spinka T.L. Le T.X. et al. Tumour-directed delivery and amplification of tumour-necrosis factor-alpha by attenuated Salmonella typhimurium Clin Cancer Res 5 1999 3822s
50. Clairmont C. Troy K. Luo X. et al. Expression of colicin E3 by tumor targeted Salmonella, enhances anti-tumor efficacy Proc Amer Assoc Cancer Res 41 2000 466
51. Hensel M. Salmonella pathogenicity island 2 Mol Microbiol 36 2000 1015-1023
52. Hensel M. Shea J.E. Waterman S.R. Genes encoding putative effector proteins of the type III secretion system of Salmonella pathogenicity island 2 are required for bacterial virulence and proliferation in macrophages Mol Microbiol 30 1998 163-174
53. Shea J.E. Hensel M. Gleeson C. Holden D.W. Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium Proc Nat Acad Sci USA 93 1996 2593-2597
54. Ochman H. Soncini F.C. Solomon F. Groisman E.A. Identification of a pathogenicity island required for Salmonella survival in host cells Proc Nat Acad Sci USA 93 1996 7800-7804
55. Cirillo D.M. Valdivia R.H. Monack D.M. Falkow S. Macrophage-dependent induction of the Salmonella pathogenicity island 2 type III secretion system and its role in intracellular survival Mol Microbiol 30 1998 175-188
56. Lostroh C.P. Bajaj V. Lee C.A. The cis requirements for transcriptional activation by HilA, a virulence determinant encoded on SPI 1 Mol Microbiol 37 2000 300-315
57. Hensel M. Functional analysis of ssaJ and the ssaK/U operon, 13 genes encoding components of the type III secretion apparatus of Salmonella pathogenicity island 2 Mol Microbiol 24 1997 155-167
58. Deiwick J. Nikolaus T. Shea J.E. et al. Mutations in Salmonella pathogenicity island 2 (SPI2) genes affecting transcription of SPI1 genes and resistance to antimicrobial agents J Bacteriol 180 1998 4775-4780
59. - mutant mouse for study of inflammation J Immunol 151 1993 1571-1578
60. Vazquez-Torres A. Jones-Carson J. Baumlert A.J. et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes Nature 401 1999 804-808
61. Uchiya K.-i. Barbieri M.A. Funato K. et al. A Salmonella virulence protein that inhibits cellular trafficking EMBO J 18 1999 3924-3933
62. Pawelek J.M. Sodi S. Chakraborty A.K. et al. Salmonella pathogenicity island-2 and anticancer activity in mice Cancer Gene Ther 9 2002 813-818
63. Bone R.C. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome.) JAMA 268 1992 3452-3455
64. Dinarello C.A. Gelfand J.A. Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome JAMA 269 1993 1829-1835
65. Somerville J.E. Cassaiano L.Jr Bainbridge B. et al. A novel Escherichia coli lipid A mutant that produces an anti-inflammatory lipopolysaccharide J Clin Invest 97 1996 359-365
66. Clementz T. Zhou Z. Raetz C.R.H. Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A J Biol Chem 272 1997 10353-10360
67. Khan S.A. Everest P. Servos S. et al. A lethal role for lipid A in Salmonella infections Mol Microbiol 29 1998 571-579
68. Murray S.R. Bermudes D. de Felipe K.S. Low K.B. Extragenic suppressors of growth defects in msbB Salmonella J Bacteriol 183 2001 5554-5561
69. Toso J.F. Gill V.J. Hwu P. et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma J Clin Oncol 20 2002 142-152
70. Rosenberg S.A. Spiess P.M. Kleiner D.E. Antitumour effects in mice of the intravenous injection of attenuated Salmonella typhimurium J Immunother 25 2002 218-225
71. Garapin A.C. Colbère-Garapin F. Cohen-Solal A. et al. Expression of herpes simples virus type I thymidine kinase gene in Escherichia coli Proc Natl Acad Sci USA 78 1981 815-819
72. Tjuvajev J. Blasberg R. Luo X. et al. Salmonella-based tumour-targeted cancer therapy: tumour amplified protein expression therapy (TAPET™) for diagnostic imaging J Control Release 74 2001 313-315
73. Platt J. Sodi S. Kelley M. et al. Antitumour effects of genetically engineered Salmonella in combination with radiation Eur J Cancer 36 2000 2397-2402
74. Peters L.J. Byers R.M. Ang K.K. Radiotherapy for melanoma Balch C.M. Houghton A.N. Milton G.W. et al. Cutaneous melanoma 2nd edn 1992 509-521 JB Lippincott Co Philadelphia